Payment overview · 2025
General Payments
$74,222.29
95 reported records · 10 companies
Healthcare provider profile · identity verified
Daniel P Duffy, MD
Allopathic & Osteopathic Physicians|Family Medicine · CEDARBURG, WI · NPI 1235191511
Verified facts
What the public records show
CMS Open Payments records show Daniel P Duffy, MD received $74,222.29 in general payments during 2025 across 95 reported records.
Axsome Therapeutics, Inc. accounted for 59.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44,125.46 | 59.5% | 45 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $7,985.03 | 10.8% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $7,761.70 | 10.5% | 17 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $5,368.57 | 7.2% | 8 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $5,339.40 | 7.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $3,374.00 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.07 | 0.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $60.53 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.52 | 0.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.01 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Honoraria | $42,625.00 | 31 |
| Consulting Fee | $15,816.50 | 5 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,125.00 | 3 |
| Travel and Lodging | $6,831.89 | 20 |
| Food and Beverage | $1,823.90 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44,125.46 | 45 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $7,929.79 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,761.70 | 17 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $5,368.57 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $137.07 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $60.53 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $55.52 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.24 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 732 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 414 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 101 |
| Irbesartan | Irbesartan | 336 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 88 |
| Lisinopril | Lisinopril | 302 | 81 |
| Bupropion Xl | Bupropion Hcl | 288 | 72 |
| Omeprazole | Omeprazole | 285 | 91 |
| Gabapentin | Gabapentin | 274 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 260 | 76 |
| Ezetimibe | Ezetimibe | 218 | 64 |
| Metformin Hcl Er | Metformin Hcl | 212 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 59 |
| Furosemide | Furosemide | 160 | 49 |
| Eliquis | Apixaban | 158 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 39 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 115 | 28 |
| Pregabalin | Pregabalin | 115 | 30 |
| Azelastine Hcl | Azelastine Hcl | 113 | 64 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 35 |
| Allopurinol | Allopurinol | 103 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 29 |
| Terbinafine Hcl | Terbinafine Hcl | 101 | 41 |
| Tramadol Hcl | Tramadol Hcl | 98 | 29 |
| Jardiance | Empagliflozin | 95 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 25 |
| Losartan Potassium | Losartan Potassium | 88 | 28 |
| Simvastatin | Simvastatin | 88 | 25 |
| Alendronate Sodium | Alendronate Sodium | 87 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 41 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 84 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 84 | 32 |
| Donepezil Hcl | Donepezil Hcl | 83 | 18 |
| Spironolactone | Spironolactone | 82 | 23 |
| Ozempic | Semaglutide | 81 | 18 |
| Celecoxib | Celecoxib | 74 | 30 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 74 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Finasteride | Finasteride | 71 | 16 |
| Trazodone Hcl | Trazodone Hcl | 71 | 25 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 69 | 21 |
| Olanzapine | Olanzapine | 69 | 13 |
| Sertraline Hcl | Sertraline Hcl | 67 | 25 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 66 | 17 |
| Memantine Hcl | Memantine Hcl | 66 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 65 | 22 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 25 |
| Mirtazapine | Mirtazapine | 63 | 18 |
| Lamotrigine | Lamotrigine | 61 | 21 |
| Montelukast Sodium | Montelukast Sodium | 59 | 21 |
| Carvedilol | Carvedilol | 58 | 13 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 14 |
| Risperidone | Risperidone | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 19 |
| Azithromycin | Azithromycin | 46 | 42 |
| Meloxicam | Meloxicam | 44 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | 12 |
| Valsartan | Valsartan | 41 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 14 |
| Loperamide | Loperamide Hcl | 40 | 15 |
| Lorazepam | Lorazepam | 39 | 16 |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 16 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 19 |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 30 |
| Famotidine | Famotidine | 30 | 12 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | 18 |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 14 |
| Bumetanide | Bumetanide | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 14 |
| Prednisone | Prednisone | 22 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Colchicine | Colchicine | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $74,222.29 · 95 records | Axsome Therapeutics, Inc. | Auvelity, CAPLYTA, JARDIANCE, Leqembi, QULIPTA, REPATHA, REXULTI, UBRELVY, VRAYLAR, WATCHMAN Access System, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error